8-K: TELA Bio Reports Record Third Quarter Revenue and Reiterates 2024 Guidance

TELA Bio announced record third-quarter revenue of $19.0 million, a 26% increase year-over-year, and reaffirmed its full-year 2024 revenue guidance.

Summary

• TELA Bio reported a record revenue of $19.0 million for the third quarter of 2024, representing a 26% increase compared to the same period in 2023.
• The company experienced a 39% and 44% year-over-year growth in unit sales volume for OviTex and OviTex PRS products, respectively.
• Gross profit for the quarter was $12.9 million, or 68% of revenue, slightly down from 69% in the same period last year due to higher inventory charges.
• Operating expenses increased to $22.2 million, up from $20.6 million in the prior year, due to higher compensation and travel costs.
• The net loss for the quarter was $10.4 million, an improvement from the $11.0 million loss in the third quarter of 2023.
• TELA Bio closed an underwritten public offering, yielding gross proceeds of approximately $46.0 million.
• The company expects to reduce operating expenses in 2025 by $5.0 million to $10.0 million from annualized first half of 2024 operating expenses.
• Full-year 2024 revenue guidance is reiterated at $74.5 million to $76.5 million, representing 27% to 31% year-over-year growth, although this may be affected by IV fluid shortages.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to record revenue, strong sales growth, successful capital raise, and reiterated guidance. However, the net loss and increased operating expenses temper the overall optimism.

Positives

• The company achieved record quarterly revenue, demonstrating strong demand for its products.
• Significant growth in unit sales volume for both OviTex and OviTex PRS products indicates increasing market adoption.
• The successful public offering provides substantial funding for future growth and operations.
• Planned operational efficiency improvements are expected to significantly reduce operating expenses in 2025.
• The company is on track to meet its full-year revenue guidance, indicating a positive growth trajectory.
• The net loss decreased compared to the same quarter last year.

Negatives

• Gross margin decreased slightly due to higher charges for excess and obsolete inventory.
• Operating expenses increased due to higher compensation costs, including severance, and increased travel and consulting expenses.
• The company reported a net loss of $10.4 million for the quarter.
• The company's cash and cash equivalents decreased to $17.3 million as of September 30, 2024, compared to $46.7 million at the end of 2023.

Risks

• Macroeconomic conditions, including potential recession, banking instability, and inflation, could impact the company's ability to market its products.
• Disruptions in the supply chain or natural disasters could affect hospital operations and procedural volumes.
• The company's ability to achieve or sustain profitability is not guaranteed.
• There is a risk that clinical study data may not be replicated in later studies or indicative of future outcomes.
• The company faces competition in the market for soft-tissue reconstruction solutions.
• IV fluid shortages resulting from recent natural disasters may affect the company's revenue projections.

Future Outlook

TELA Bio expects to reduce operating expenses in 2025 and has reiterated its full-year 2024 revenue guidance of $74.5 million to $76.5 million, representing 27% to 31% year-over-year growth. The company believes it is amply funded to attain profitability with current resources.

Management Comments

• Third quarter revenue of $19 million was the highest in TELA Bio's history and indicates a healthy demand for our products and a return to normalized growth across the OviTex portfolio.
• Our commercial leadership is prioritizing growth, and we are confident in our ability to demonstrate increased operating leverage going forward.
• With an additional $43 million in net proceeds following the recent underwritten public offering, and actions already taken to reduce operating expenses for 2025, we believe that we are amply funded to attain profitability with current resources.

Industry Context

The announcement reflects TELA Bio's position in the growing market for soft-tissue reconstruction solutions, particularly in hernia repair. The company is competing with both traditional synthetic meshes and biologic alternatives, emphasizing its reinforced tissue matrix products as a more natural and effective option. The company is also expanding into the plastic and reconstructive surgery market.

Comparison to Industry Standards

• TELA Bio's 26% revenue growth in Q3 2024 is strong compared to the overall medical device industry, which typically sees single-digit growth rates.
• The company's gross margin of 68% is within the typical range for medical device companies, but the slight decrease indicates potential cost pressures.
• The company's focus on reinforced tissue matrix products aligns with a trend towards more natural and less invasive solutions in soft-tissue reconstruction, contrasting with companies that rely heavily on synthetic meshes, such as Medtronic and Johnson & Johnson.
• TELA Bio's clinical data, particularly the BRAVO study, is being used to demonstrate the efficacy of their products compared to biologics like Strattice and Surgimend, which are offered by companies such as Allergan and Integra LifeSciences.
• The company's expansion into robotic and minimally invasive surgery aligns with industry trends towards less invasive procedures, which is also a focus for companies like Intuitive Surgical.

Stakeholder Impact

• Shareholders will benefit from the increased revenue and potential for future profitability.
• Employees may experience changes due to the implemented operational efficiency improvements.
• Customers (surgeons and hospitals) will have access to innovative soft-tissue reconstruction solutions.
• Suppliers may see increased demand for materials used in TELA Bio's products.
• Creditors may view the company more favorably due to the improved financial performance and successful capital raise.

Next Steps

• TELA Bio will host a conference call on November 7, 2024, to discuss its third quarter 2024 financial results.
• The company will continue to implement operational efficiency improvements to reduce operating expenses in 2025.
• The company will focus on driving commercial adoption of its products through a targeted direct-sales approach.

Key Dates

Keywords

TELA Bio, OviTex, OviTex PRS, soft-tissue reconstruction, medical technology, hernia repair, reinforced tissue matrix, financial results, revenue, operating expenses, public offering, gross margin, net loss